"Geopolitical events, judicial rulings, new law legislation, and policy changes are all circumstances occurring on domestic and international stages that are triggering big stock moves in various industrial sectors. The impact is being demonstrated on both large-cap and small-cap companies. While investing in companies that are exhibiting potential large growth prospects for the coming 12-months is always finding companies with the addition of a dividend is always a welcome bonus."
"In August 20224, Morgan Stanley predicted a price target of $250.00, when Abbvie Inc. (NYSE: ABBV) was trading at $189.00 At the time of this writing, it is trading between $235 and its 52-week high of $244.81. Perhaps a few weeks off, but certainly on track. Its 2.79% yield is also a nice cherry on top of a lucrative stock."
Geopolitical events, judicial rulings, new legislation, and policy changes are driving significant stock moves across industrial sectors and affecting both large-cap and small-cap companies. Investors favor companies showing substantial growth potential over the next 12 months and often prefer those that pay dividends. AbbVie Inc., headquartered in Chicago, ranks among the top five biotech and pharmaceutical companies and markets treatments for blood, skin, prostate, organ cancers, autoimmune diseases, and gastrointestinal disorders, along with Botox and cosmetic products. AbbVie's stock recently approached analyst targets and yields 2.79%. Newly approved Emrelis targets C‑MET biomarkers to precisely attack small-cell lung tumors with a distinct mechanism from HER2 or TROP2 therapies.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]